Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 19/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777464 | 1.00 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL13018232 | 1.00 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL3777466 | 1.00 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL30990404 | 1.00 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL29379519 | 1.00 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL4563844 | 1.00 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL3782166 | 0.95 | TRPV1 (0.49) | TRPV1 | |
| SCHEMBL3782163 | 0.95 | TRPV1 (0.49) | TRPV1 | |
| SCHEMBL3782164 | 0.95 | TRPV1 (0.49) | TRPV1 | |
| SCHEMBL4434439 | 0.95 | TRPV1 (0.49) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11998633-B2 | Topical sol-gel composition for the treatment of dermatitis | AMOREPACIFIC CORPORATION (KR) | 2024-06-04 | — | — | US | claimed |
| US-11957669-B2 | Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide | AMOREPACIFIC CORPORATION (KR) | 2024-04-16 | — | — | US | claimed |
| CN-112996489-A | Sol-gel composition | 株式会社爱茉莉太平洋 | 2021-06-18 | — | — | CN | claimed |
| US-20200405701-A1 | PHARMACEUTICAL COMPOSITION CONTAINING (R)-N-[1-(3,5-DIFLUORO-4-METHANESULFONYLAMINO-PHENYL)-ETHYL]-3-(2-PROPYL-6-TRIFLUOROMETHYLPYRIDIN-3-YL)-ACRYLAMIDE AND METHOD FOR INHIBITING CRYSTAL FORMATION THEREOF | AMOREPACIFIC CORPORATION (KR) | 2020-12-31 | — | — | US | claimed |
| CN-106660949-B | Chiral resolution method of N- [4- (1-aminoethyl) -phenyl ] -sulfamide derivative | 株式会社爱茉莉太平洋 | 2020-11-13 | — | — | CN | claimed |
| US-20200215040-A1 | PHARMACEUTICAL COMPOSITION CONTAINING (R)-N-[1-(3,5-DIFLUORO-4-METHANSULFONYLAMINO-PHENYL)-ETHYL]-3-(2-PROPYL-6-TRIFLUOROMETHYL-PYRIDIN-3-YL)-ACRYLAMIDE | AMOREPACIFIC CORPORATION (KR) | 2020-07-09 | — | — | US | claimed |
| EP-3666254-A2 | PHARMACEUTICAL COMPOSITION CONTAINING (R)-N-[1-(3,5-DIFLUORO-4-METHANSULFONYLAMINO-PHENYL)-ETHYL]-3-(2-PROPYL-6-TRIFLUOROMETHYL-PYRIDIN-3-YL)-ACRYLAMIDE | Amorepacific Corporation (KR) | 2020-06-17 | — | — | EP | claimed |
| CN-110996908-A | Pharmaceutical compositions comprising (R) -N- [1- (3, 5-difluoro-4-methanesulfonylamino-phenyl) -ethyl ] -3- (2-propyl-6-trifluoromethyl-pyridin-3-yl) -acrylamide | 株式会社爱茉莉太平洋 | 2020-04-10 | — | — | CN | claimed |
| EP-2054411-B1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORP (KR) | 2014-08-20 | — | — | EP | claimed |
| US-7858621-B2 | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | AMOREPACIFIC CORPORATION (KR) | 2010-12-28 | — | — | US | claimed |
| EP-2054411-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2009-05-06 | — | — | EP | claimed |
| WO-2008013414-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2008-01-31 | — | — | WO | claimed |
| EP-3677264-B1 | COMPOSITION FOR PREVENTING OR TREATING ATOPIC DERMATITIS | AMOREPACIFIC CORP (KR) | 2025-03-19 | — | — | EP | disclosed |
| EP-3666254-C0 | PHARMACEUTICAL COMPOSITION CONTAINING (R)-N-[1-(3,5-DIFLUORO-4-METHANSULFONYLAMINO-PHENYL)-ETHYL]-3-(2-PROPYL-6-TRIFLUOROMETHYL-PYRIDIN-3-YL)-ACRYLAMIDE | AMOREPACIFIC CORP (KR) | 2024-12-04 | — | — | EP | disclosed |
| EP-3666254-B1 | PHARMACEUTICAL COMPOSITION CONTAINING (R)-N-[1-(3,5-DIFLUORO-4-METHANSULFONYLAMINO-PHENYL)-ETHYL]-3-(2-PROPYL-6-TRIFLUOROMETHYL-PYRIDIN-3-YL)-ACRYLAMIDE | AMOREPACIFIC CORP (KR) | 2024-12-04 | — | — | EP | disclosed |
| US-12059412-B2 | Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethylpyridin-3-yl)-acrylamide and method for inhibiting crystal formation thereof | AMOREPACIFIC CORPORATION (KR) | 2024-08-13 | — | — | US | disclosed |
| US-7858621-B2 | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | AMOREPACIFIC CORPORATION (KR) | 2010-12-28 | — | — | US | disclosed |
| EP-2054411-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2009-05-06 | — | — | EP | disclosed |
| US-20080312234-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2008-12-18 | — | — | US | disclosed |
| WO-2008013414-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312234-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885 |
| US-20200215040-A1 | PHARMACEUTICAL COMPOSITION CONTAINING (R)-N-[1-(3,5-DIFLUORO-4-METHANSULFONYLAMINO-PHENYL)-ETHYL]-3-(2-PROPYL-6-TRIFLUOROMETHYL-PYRIDIN-3-YL)-ACRYLAMIDE | CTRC, HTR3C, ACR | TRPV1 1783/4885 |
| US-12059412-B2 | Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethylpyridin-3-yl)-acrylamide and method for inhibiting crystal formation thereof | SULT2A1, SULT1E1, SULT1A1 | TRPV1 2202/4885 |
| US-11957669-B2 | Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide | CTRC, HTR3C, ACR | TRPV1 1783/4885 |
| US-20200405701-A1 | PHARMACEUTICAL COMPOSITION CONTAINING (R)-N-[1-(3,5-DIFLUORO-4-METHANESULFONYLAMINO-PHENYL)-ETHYL]-3-(2-PROPYL-6-TRIFLUOROMETHYLPYRIDIN-3-YL)-ACRYLAMIDE AND METHOD FOR INHIBITING CRYSTAL FORMATION THEREOF | SULT2A1, SULT1E1, SULT1A1 | TRPV1 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.